BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone® High-Dose Influenza Vaccine. Expert Rev Vaccines 2016;15:1495-505. [PMID: 27813430 DOI: 10.1080/14760584.2016.1254044] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Devi AB, Sarala R. Substantial effect of phytochemical constituents against the pandemic disease influenza-a review. Futur J Pharm Sci 2021;7:120. [PMID: 34150912 DOI: 10.1186/s43094-021-00269-5] [Reference Citation Analysis]
2 Whiskin C, Cutcliffe N. Opportunities for pharmacists in vaccinating higher-risk populations. Can Pharm J (Ott) 2019;152:418-23. [PMID: 31762856 DOI: 10.1177/1715163519877898] [Reference Citation Analysis]
3 Caldera F, Mercer M, Samson SI, Pitt JM, Hayney MS. Influenza vaccination in immunocompromised populations: Strategies to improve immunogenicity. Vaccine 2021;39 Suppl 1:A15-23. [PMID: 33422377 DOI: 10.1016/j.vaccine.2020.11.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Greenberg DP, Robertson CA, Talbot HK, Decker MD. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older. Hum Vaccin Immunother 2017;13:2058-64. [PMID: 28700265 DOI: 10.1080/21645515.2017.1344375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Wen S, Wu Z, Zhong S, Li M, Shu Y. Factors influencing the immunogenicity of influenza vaccines. Hum Vaccin Immunother 2021;17:2706-18. [PMID: 33705263 DOI: 10.1080/21645515.2021.1875761] [Reference Citation Analysis]
6 Mattock R, Gibbons I, Moss J, Mealing S, Largeron N, Carroll S, Alvarez FP. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales. J Med Econ 2021;24:1261-71. [PMID: 34726129 DOI: 10.1080/13696998.2021.2000780] [Reference Citation Analysis]
7 Noh JY, Jang YS, Lee SN, Choi MJ, Yoon JG, Yu DH, Song JY, Cheong HJ, Kim WJ. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults. Vaccine 2019;37:5171-6. [PMID: 31377075 DOI: 10.1016/j.vaccine.2019.07.076] [Reference Citation Analysis]
8 Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK; QHD00013 Study Group. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial. Vaccine 2019;37:5825-34. [PMID: 31431411 DOI: 10.1016/j.vaccine.2019.08.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
9 Ng TWY, Cowling BJ, Gao HZ, Thompson MG. Comparative Immunogenicity of Enhanced Seasonal Influenza Vaccines in Older Adults: A Systematic Review and Meta-analysis. J Infect Dis 2019;219:1525-35. [PMID: 30551178 DOI: 10.1093/infdis/jiy720] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
10 Rouphael NG, Lai L, Tandon S, McCullough MP, Kong Y, Kabbani S, Natrajan MS, Xu Y, Zhu Y, Wang D, O'Shea J, Sherman A, Yu T, Henry S, McAllister D, Stadlbauer D, Khurana S, Golding H, Krammer F, Mulligan MJ, Prausnitz MR. Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial. NPJ Vaccines 2021;6:89. [PMID: 34262052 DOI: 10.1038/s41541-021-00353-0] [Reference Citation Analysis]
11 Nuwarda RF, Alharbi AA, Kayser V. An Overview of Influenza Viruses and Vaccines. Vaccines (Basel) 2021;9:1032. [PMID: 34579269 DOI: 10.3390/vaccines9091032] [Reference Citation Analysis]
12 Richards KA, Moritzky S, Shannon I, Fitzgerald T, Yang H, Branche A, Topham DJ, Treanor JJ, Nayak J, Sant AJ. Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans. NPJ Vaccines 2020;5:77. [PMID: 32884842 DOI: 10.1038/s41541-020-00227-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
13 Sanchez L, Matsuoka O, Inoue S, Inoue T, Meng Y, Nakama T, Kato K, Pandey A, Chang LJ. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial. Hum Vaccin Immunother 2020;16:858-66. [PMID: 31634025 DOI: 10.1080/21645515.2019.1677437] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Robison SG, Thomas AR. Assessing the effectiveness of high-dose influenza vaccine in preventing hospitalization among seniors, and observations on the limitations of effectiveness study design. Vaccine 2018;36:6683-7. [PMID: 30287157 DOI: 10.1016/j.vaccine.2018.09.050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
15 Jennings S, Swiderek J, Sawyer JR, Cha R. Continued consideration for high dose influenza vaccine in persons living with HIV. Future Virology 2019;14:605-15. [DOI: 10.2217/fvl-2019-0091] [Reference Citation Analysis]
16 Kallon S, Samir S, Goonetilleke N. Vaccines: Underlying Principles of Design and Testing. Clin Pharmacol Ther 2021;109:987-99. [PMID: 33705574 DOI: 10.1002/cpt.2207] [Reference Citation Analysis]
17 Cunningham AL, McIntyre P, Subbarao K, Booy R, Levin MJ. Vaccines for older adults. BMJ 2021;372:n188. [PMID: 33619170 DOI: 10.1136/bmj.n188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Loperto I, Simonetti A, Nardone A, Triassi M. Use of adjuvanted trivalent influenza vaccine in older-age adults: a systematic review of economic evidence. Hum Vaccin Immunother 2019;15:1035-47. [PMID: 30735465 DOI: 10.1080/21645515.2019.1578597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Krammer F. The human antibody response to influenza A virus infection and vaccination. Nat Rev Immunol 2019;19:383-97. [PMID: 30837674 DOI: 10.1038/s41577-019-0143-6] [Cited by in Crossref: 162] [Cited by in F6Publishing: 149] [Article Influence: 81.0] [Reference Citation Analysis]
20 Gorse GJ, Grimes S, Buck H, Mulla H, White P, Hill H, May J, Frey SE, Blackburn P. MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly. Vaccine 2022:S0264-410X(22)00059-7. [PMID: 35125224 DOI: 10.1016/j.vaccine.2022.01.035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lee P, Kim DJ. Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19. Immune Netw 2020;20:e28. [PMID: 32895615 DOI: 10.4110/in.2020.20.e28] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Antonelli Incalzi R, Trevisan C, Del Signore S, Volpato S, Fumagalli S, Monzani F, Bellelli G, Gareri P, Mossello E, Malara A, Coin A, Zia G, Ranhoff AH. Are vaccines against COVID-19 tailored to the most vulnerable people? Vaccine 2021;39:2325-7. [PMID: 33810907 DOI: 10.1016/j.vaccine.2021.03.066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hall LL, Xu L, Mahmud SM, Puckrein GA, Thommes EW, Chit A. A Map of Racial and Ethnic Disparities in Influenza Vaccine Uptake in the Medicare Fee-for-Service Program. Adv Ther 2020;37:2224-35. [PMID: 32274750 DOI: 10.1007/s12325-020-01324-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
24 Gouma S, Zost SJ, Parkhouse K, Branche A, Topham DJ, Cobey S, Hensley SE. Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines During the 2017-2018 Season. Clin Infect Dis 2020;71:1447-53. [PMID: 31598646 DOI: 10.1093/cid/ciz996] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
25 Samson SI, Leventhal PS, Salamand C, Meng Y, Seet BT, Landolfi V, Greenberg D, Hollingsworth R. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis. Expert Review of Vaccines 2019;18:295-308. [DOI: 10.1080/14760584.2019.1575734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
26 Roubidoux EK, Schultz-Cherry S. Animal Models Utilized for the Development of Influenza Virus Vaccines. Vaccines (Basel) 2021;9:787. [PMID: 34358203 DOI: 10.3390/vaccines9070787] [Reference Citation Analysis]
27 Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing 2019;16:25. [PMID: 31528180 DOI: 10.1186/s12979-019-0164-9] [Cited by in Crossref: 113] [Cited by in F6Publishing: 101] [Article Influence: 37.7] [Reference Citation Analysis]
28 Schaffner W, Chen WH, Hopkins RH, Neuzil K. Effective Immunization of Older Adults Against Seasonal Influenza. Am J Med 2018;131:865-73. [PMID: 29544989 DOI: 10.1016/j.amjmed.2018.02.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
29 Vogel OA, Manicassamy B. Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics. Front Microbiol 2020;11:135. [PMID: 32117155 DOI: 10.3389/fmicb.2020.00135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
30 Colrat F, Thommes E, Largeron N, Alvarez FP. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review. Vaccine 2021;39 Suppl 1:A42-50. [PMID: 33518466 DOI: 10.1016/j.vaccine.2020.12.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
31 Allen JC, Toapanta FR, Chen W, Tennant SM. Understanding immunosenescence and its impact on vaccination of older adults. Vaccine 2020;38:8264-72. [PMID: 33229108 DOI: 10.1016/j.vaccine.2020.11.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
32 Damodharan K, Arumugam GS, Ganesan S, Doble M, Thennarasu S. A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2. RSC Adv 2021;11:20006-35. [PMID: 35479882 DOI: 10.1039/d0ra09668g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Cataldi JR, Hurley LP, Lindley MC, O'Leary ST, Gorman C, Brtnikova M, Beaty BL, Crane LA, Shay DK, Kempe A. Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians. J Gen Intern Med 2021;36:2030-8. [PMID: 33483822 DOI: 10.1007/s11606-020-06397-7] [Reference Citation Analysis]
34 Koroleva M, Batarse F, Moritzky S, Henry C, Chaves F, Wilson P, Krammer F, Richards K, Sant AJ. Heterologous viral protein interactions within licensed seasonal influenza virus vaccines. NPJ Vaccines 2020;5:3. [PMID: 31934357 DOI: 10.1038/s41541-019-0153-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]